Evolut TAVR 2.3 cm2 vs. SAVR 2.0 cm2
15% Larger EOAs
Evolut TAVR 8.6 mm Hg vs. SAVR 11.2 mm Hg
23% Lower Gradients
As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months1
5.3% TAVR vs. 6.7% SAVR
n = 1,468
Evolut TAVR showed lower mortality, fewer disabling strokes, and fewer heart failure rehospitalizations compared to SAVR2
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.
Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.